

California State Board of Pharmacy 2720 Gateway Oaks Drive, Ste. 100 Sacramento, CA 95833 Phone: (916) 518-3100 Fax: (916) 574-8618

www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency Department of Consumer Affairs Gavin Newsom, Governor



DRAFT HOSPITAL PHARMACY SELF-ASSESSMENT

Title 16 of the California Code of Regulations section 1715 requires the pharmacist-in-charge of each pharmacy licensed under section 4037 or 4029 of the Business and Professions Code (BPC) to complete a self-assessment of the pharmacy's compliance with federal and state pharmacy law. The assessment shall be performed before July 1 of every odd-numbered year. The pharmacist-incharge must also complete a self-assessment within 30 days whenever (1) a new pharmacy permit has been issued, or (2) there is a change in the pharmacist-in-charge. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

The self-assessment must be completed in its entirety. It may be completed online and printed, initialed, signed (the Boards digital signature policy is available here), and readily available in the pharmacy. Do not copy a previous assessment.

Notes: If dispensing prescriptions for outpatient use, a Community Pharmacy Self-Assessment/Hospital Outpatient Pharmacy Self-Assessment (17M-13, pursuant to 16 CCR 1715) must be completed also. A hospital that compounds drug products must also complete the Compounding Self-Assessment (17M-39 pursuant to 16 CCR 1735.2(k).)

Each self-assessment must be kept on file in the pharmacy for three years after it is performed.

Pharmacy Name:		
Address:	Phone:	
Ownership: □Sole Owner □Partners □ Non-Licensed Owner □	ship □Corporation □LLC □Trust □ Other (please specify) Exp. Date:	
License #: Exp. Date:	Other License #: Exp. Date:	
Licensed Sterile Compounding License #	Expiration:	
Accredited by (optional): From: To:		
Centralized Hospital Packaging #: Exp. Date:		
DEA Registration #: Exp	. Date: Date of DEA Inventory:	
Hours: Weekdays Sat	Sun 24 Hours	
PIC:	RPH # Exp. Date:	
	PIC	

Pharmacy staff (pharmacists, interns, technicians):
APH= Advanced Practice Pharmacist, DEA = Drug Enforcement Administration.

1	RPH#	Exp. Date:
	APH #	Exp. Date:
	DEA #	Exp. Date:
2	RPH#	Exp. Date:
	APH #	Exp. Date:
	DEA #	Exp. Date:
3	RPH#	Exp. Date:
	APH #	Exp. Date:
	DEA #	Exp. Date:
4	RPH#	Exp. Date:
		Exp. Date:
	APH # DEA #	Exp. Date:
5	RPH#	Exp. Date:
o	APH #	Exp. Date:
	DEA #	Exp. Date:
6		
7		Exp. Date:
8	INT #	Exp. Date:
9	INT #	Exp. Date:
10	TCH#	Exp. Date:
11	TCH#	Exp. Date:
12	TCH#	Exp. Date:
13	TCH#	Exp. Date:

HOSPITAL PHARMACY SELF-ASSESSMENT

All references to the California Code of Regulations (CCR) are Title 16 unless otherwise noted.

Please mark the appropriate box for each question. If "NO," enter an explanation on "CORRECTIVE ACTION or ACTION PLAN" lines below. If more space is needed, you may add additional sheets.

1. Ph Yes No N/A	narmacy
	1.1. The pharmacy is secure and has provisions for effective control against the theft of dangerous drugs and devices. (BPC 4116, 4117, CCR 1714)
	1.2. The pharmacy has procedures in place to take action to protect the public when a licensed individual employed by or with the pharmacy is discovered or known to be chemically, mentally, or physically impaired to the extent it affects their ability to practice the profession or occupation authorized by their license, or is discovered or known to have engaged in the theft, diversion, or self-use of dangerous drugs(BPC 4104[a])
	1.3. The pharmacy has written policies and procedures for addressing chemical, mental, or physical impairment, as well as theft, diversion, or self-use of dangerous drugs, among licensed individual employed by or with the pharmacy. (BPC 4104[b])
	1.4. The pharmacy reports to the board within 14 days of the receipt or development of the following information with regard to any licensed individual employed by or with the pharmacy: (1) any admission by a licensed individual of chemical, mental, or physical impairment affecting their ability to practice; (2) Any admission by a licensed individual of theft, diversion, or self-use of dangerous drugs; (3) Any video or documentary evidence demonstrating chemical, mental, or physical impairment of a licensed individual to the extent it affects their ability to practice; (4) Any video or documentary evidence demonstrating theft, diversion, or self-use of dangerous drugs by a licensed individual; (5) Any termination based on chemical, mental, or physical impairment of a licensed individual to the extent it affects their ability to practice; (6) Any termination of a licensed individual based on theft, diversion, or self-use of dangerous drugs. (BPC 4104[c])
	1.5. The pharmacy maintains a supply of medications which are accessible without entering the pharmacy during hours when the pharmacy is closed, and the pharmacist is not available. Access is limited to designated registered nurses. (22 CCR 70263[n])
	1.6. The pharmacy is of sufficient size and has an unobstructed area to accommodate the safe practice of pharmacy. (CCR 1714[b])
	1.7. The pharmacy premises, fixtures, and equipment are maintained in a clean and orderly condition. (CCR 1714[c])
	1.8. The pharmacy sink has hot and cold running water. (CCR 1714[c])
	1.9. The pharmacy has a readily accessible restroom. (CCR 1714[g])
	1.10. The original board-issued pharmacy license and the current renewal are posted where they may be clearly read by the purchasing public. (BPC 4032, 4058)

	 1.11. Pharmacists, interns, pharmacy technicians, and pharmacy technician trainees wear nametags, in 18-point type, that contain their name and license status. (BPC 680, 4115.5[e], CCR 1793.7[c])
	1.12. Does the pharmacy compound sterile drugs?
	(If yes, complete the Compounding Self-Assessment required by CCR 1735.2[k])
	1.13. The pharmacy is subscribed to the board's email notifications. (BPC 4013)
	Date Last Notification Received:
	Email address registered with the board:
	1.14. For a pharmacy whose owner owns two or more pharmacies, the pharmacy receives the board's email notifications through the owner's electronic notice system. (BPC 4013[c])
	Date Last Notification Received:
	Email address registered with the board:
2. Nu	rsing Stations
Yes No N/A	2.1. Adequate space is available at ward or nursing station for the storage of drugs and preparation of medication dosesAll such spaces and areas can be locked and are accessible to authorized personnel only. (22 CCR 70269)
	2.2. The pharmacist, intern pharmacist, or pharmacy technician completes the monthly inspections of all floor stock and drugs maintained in nursing stations. Any irregularities are reported to the director of nursing services, and as required by hospital policy.
	(BPC 4119.7[c], 4115[j], 22 CCR 70263[q][10])
	 (BPC 4119.7[c], 4115[j], 22 CCR 70263[q][10]) □ 2.2.1. An intern pharmacist shall report any irregularities to the pharmacist. (BPC 4119.7[c])
CORRE	 (BPC 4119.7[c], 4115[j], 22 CCR 70263[q][10]) □ 2.2.1. An intern pharmacist shall report any irregularities to the pharmacist. (BPC 4119.7[c]) □ 2.2.2. Any irregularities discovered by a pharmacy technician shall be reported to the pharmacist-in-charge and to the director or chief executive officer of the health
CORRE	 (BPC 4119.7[c], 4115[j], 22 CCR 70263[q][10]) □ 2.2.1. An intern pharmacist shall report any irregularities to the pharmacist. (BPC 4119.7[c]) □ 2.2.2. Any irregularities discovered by a pharmacy technician shall be reported to the pharmacist-in-charge and to the director or chief executive officer of the health care facility within 24 hours. (BPC 4115[j][3])

3. Delivery of Drugs

O. Do	voly of Brugo
Yes No N/A	3.1. Delivery to the pharmacy of dangerous drugs and dangerous devices are only delivered to the licensed premise and signed for and received by a pharmacist. (BPC 4059.5[a])
	3.2. Deliveries to a hospital pharmacy may be made to a central receiving location within the hospital. However, the dangerous drugs or dangerous devices shall be delivered to the licensed pharmacy premise within one working day following receipt by the hospital, and the pharmacist on duty at that time shall immediately inventory the drugs or devices. (BPC 4059.5[c])
	3.3. A pharmacy may take delivery of dangerous drugs and dangerous devices when the pharmacy is closed and no pharmacist is on duty if all of the following requirements are met: (BPC 4059.5[f])
	 3.3.1. The drugs are placed in a secure storage facility in the same building as the pharmacy; (BPC 4059.5[f][1])
	 3.3.2. Only the pharmacist-in-charge or a pharmacist designated by the pharmacist-in-charge has access to the secure storage facility after dangerous drugs or dangerous devices have been delivered; (BPC 4059.5[f][2])
	 3.3.3. The secure storage facility has a means of indicating whether it has been entered after dangerous drugs or dangerous devices have been delivered; (BPC 4059.5[f][3])
	 3.3.4. The pharmacy maintains written policies and procedures for the delivery of dangerous drugs and dangerous devices to a secure storage facility; and (BPC 4059.5[f][4])
	□ 3.3.5. The agent delivering dangerous drugs and dangerous devices pursuant to this subdivision leaves documents indicating the name and amount of each dangerous drug or dangerous device delivered in the secure storage facility. The pharmacy shall be responsible for the dangerous drugs and dangerous devices delivered to the secure storage facility. The pharmacy shall also be responsible for obtaining and maintaining records relating to the delivery of dangerous drugs and dangerous devices to a secure storage facility. (BPC 4059.5[f][5])
□□□ 3.	4. Prior to, or at the time of, accepting ownership of a product included in the Drug Supply Chain Security Act from an authorized trading partner, the pharmacy is provided transaction history, transaction information, and a transaction statement. (21 USC 360eee-1[d][1][A][i])
□□□ 3.	5. Prior to, or at the time of, each transaction in which the pharmacy transfers ownership of a product included in the Drug Supply Chain Security Act to an authorized trading partner, the subsequent owner is provided transaction history, transaction information, and a transaction statement for the product. Note: This requirement does not apply to sales by a pharmacy to another pharmacy to fulfill a specific patient need. (21 USC 360eee-1[d][1][A][ii])

Yes No N/A □□□ 3.	6. The pharmacy captures transaction information (including lot level information, if provided), transaction history, and transaction statements, as necessary to investigate a suspect product, and maintains such information, history, and statements for not less than 6 years after the transaction. (21 USC 360eee-1[d][1][A][iii])		
□□□ 3.7. The pharmacy has lot-level and unit-level traceability in accordance with the Drug C and Security Act (DQSA). (21 USC 360eee-1[d][2] and 582[g][1])			
CORREC	CTIVE ACTION OR ACTION PLAN:		
	g Stock		
Yes No N/A	4.1. The drug stock is clean, orderly, properly stored, properly labeled and in-date. (21 USC sections 331, 351, 352, BPC 4169[a][2]-[4], 4342, HSC 111255, 111335, CCR 1714[b], 22 CCR 70263[q])		
	4.2. All ward/floor drug stock and drug supplies that are maintained for access when the pharmacist is not available are properly labeled and stored. Records of drugs taken from the drug stock or drug supplies must be maintained and the pharmacist must be notified. (22 CCR 70263[n])		
	4.3. Preferentially priced drugs are furnished solely or predominately to inpatients in accordance with provisions of the Nonprofit Institutions Act (15 USC 13c). Such drugs also may be dispensed pursuant to prescriptions for inpatients at the time of discharge, for employees of the hospital, or on an emergency basis for a walk-in customer (provided that sales to walk-ins do not exceed one percent of the pharmacy's total prescription sales) or to any person in the occasional emergency situation where no other sources are readily available in the community to meet the emergency need. (BPC 4380, CCR 1710[a])		
	4.4. All unit-dose drugs received from a centralized hospital packaging pharmacy are correctly labeled, are barcoded, and the barcode is readable at the patient's bedside. (BPC 4128.4, 4128.5)		
	4.5. All drugs are maintained in accordance with national standards regarding the storage area and refrigerator or freezer temperature and manufacturer's guidelines. (BPC 4119.7[b]		
	4.6. Dangerous drugs or dangerous devices are purchased, traded, sold or transferred with an entity licensed with the board as a wholesaler, third-party logistics provider, pharmacy or a manufacturer, and provided the dangerous drugs and devices: (BPC 4059.5, 4169, CCR 1718.1)		
	4.6.1. Are not known or reasonably should not be known to the pharmacy as being adulterated.		
	4.6.2. Are not known or reasonably should not be known to the pharmacy as being misbranded.		

	□ 4.6.3. Are not expired.
Yes No N/A	4.7. If the pharmacy has reasonable cause to believe a dangerous drug or dangerous device in, or having been in its possession is counterfeit or the subject of a fraudulent transaction, the pharmacy will notify the board within 72 hours of obtaining that knowledge. (BPC 4107.5)
	4.8. The pharmacy does not furnish dangerous drugs or dangerous devices to an unauthorized person. (BPC 4163)
	4.9. An automated unit dose system (AUDS) operated by a licensed hospital pharmacy as defined by BPC 4029, and used solely to provide doses administered to patients while in a licensed general acute care hospital facility shall be exempted from the requirement of obtaining an ADDS license if the hospital pharmacy owns or leases the AUDS and owns the dangerous drugs or devices in the AUDS. The AUDS shall comply with all other requirements for an ADDS (i.e. Security, Record keeping, Self-Assessment, Quality Assurance, etc.) and maintain a list of the location of each AUDS it operates. (BPC 4119.11[b][3], 4427.2, 4427.65)
CORREC	CTIVE ACTION OR ACTION PLAN:
Dis	rmacies That Donate Drugs to a Voluntary County-Approved Drug Repository and tribution Program
Yes No N/A	5.1. Does the pharmacy donate to or operate a county-approved Voluntary Drug Repository and Distribution Program?
	□ 5.1.1. The pharmacy that donates medications to or operates a voluntary county approved drug repository and distribution program meets all the requirements as specified in law. (HSC 150200, 150201, 150202, 150202.5, 150203, 150204, 150204.5, 150204.6, 150205, BPC 4169.5)
6. Phari	nacist-in-Charge (PIC)
Yes No N/A	6.1. The pharmacy has a PIC who is responsible for the daily operation of the pharmacy. (BPC 4101, 4113, 4305, 4330, CCR 1709, 1709.1)
	6.2. The PIC has adequate authority to assure the pharmacy's compliance with laws governing the operation of a pharmacy. (CCR 1709.1[b])
	6.3. Is the PIC in charge of another pharmacy?
	If yes, the pharmacies are within 50 driving distance miles of each other. (CCR 1709.1[c])
	If yes, name of other pharmacy

Yes No N/A		y change of PIC is reported by the pharmacy and the departing PIC to the board in ng within 30 days. (BPC 4101, 4330)
		e PIC is not concurrently serving as the designated representative-in-charge for a lesaler or veterinary food-animal drug retailer. (CCR 1709.1[d])
	ensu or of and	e PIC or pharmacist, if the PIC is not available, may make staffing decisions to ure sufficient personnel are present in the pharmacy to prevent fatigue, distraction, ther conditions that may interfere with a pharmacist's ability to practice competently safely. This paragraph does not apply to facilities of the Department of Corrections Rehabilitation. (BPC 4113[c][2])
	cond patie hour	e PIC or pharmacist on duty shall immediately notify the store management of any ditions that present an immediate risk of death, illness, or irreparable harm to ents, personnel, or pharmacy staff. If the conditions are not resolved within 24 rs, the PIC or pharmacist on duty shall ensure the board is timely notified. (BPC 3[d][1])
CORRE	CTIVE AC	CTION OR ACTION PLAN:
7. Dutie Yes No N/A □□□		narmacist harmacist: (BPC 4019, 4051, 4052, 4052.2, CCR 1717[c], CCR 1793.1, CCR 3.7)
		7.1.1. Receives a chart order for an inpatient; (BPC 4019, 4051-[b], 4052, 4052.2, CCR 1717, CCR 1793.1[a])
		7.1.2. Identifies, evaluates and interprets the chart order; (CCR 1717[c], CCR 1793.1[c])
		7.1.3. Reviews patient's drug regimen and interprets the clinical data in the patient's medication record; (BPC 4052.1[a][4], 4052.2[a][4], CCR 1793.1[d])
		7.1.4. Consults with any prescriber, nurse or health care professional; (CCR 1793.1[e])
		7.1.5. Calculates drug doses; (BPC 4052[a][3], 4052.2[a][3], 4052.2[a][4])
		7.1.6. Supervises the packaging of drugs and checks the packaging procedures and products upon completion; (CCR 1793.1[f])
		7.1.7. Is responsible for all activities of pharmacy technicians, interns and clerks related to the furnishing of drugs to ensure that all such activities are performed completely, safely and without risk of harm to patients; (CCR 1793.7[e])
		7.1.8. Performs any other duty which federal or state law or regulation authorizes only a registered pharmacist to perform; and performs all functions which require professional judgment. (BPC 4052, 4052.2, CCR 1793.1[g])

functions are doing so in accordance with the hospital's policies, procedures and protocols which have been developed by health professionals including physicians, pharmacists, and registered nurses, with the concurrence of the facility administrator: (BPC 4027, 4051, 4052, 4052.2) 7.2.1. Ordering or performing routine drug therapy-related patient assessment procedures; (BPC 4052.1[a][1]; 4052.2[a][1]) 7.2.2. Ordering drug therapy-related laboratory tests; administering drugs or biologicals by injection; (BPC 4052.1[a][2],[3]; 4052.2[a][2],-[3]) 7.2.3. Initiating or adjusting the drug regimen of a patient; (BPC 4052.1[a][4], BF 4052.2[a][4]) 7.2.4. Performing moderate or waived laboratory tests. Prior to performing any of these functions, the pharmacist must have either (1) successfully completed clinical residency training, or (2) demonstrated clinical experience in direct paties care delivery as specified in BPC section 4052.2[d]. (BPC 4052.4) 7.2.5. A pharmacist may perform any aspect of any FDA-approved or authorized test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness, condition or disease being tested as applicable. (BPC 4052.4) 7.3. The pharmacist who is authorized to issue an order to initiate or adjust a controlle substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.5. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histo of a patient. Upon approval, the	Yes No N/A			
procedures; (BPC 4052.1[a][1]; 4052.2[a][1]) 7.2.2. Ordering drug therapy-related laboratory tests; administering drugs or biologicals by injection; (BPC 4052.1[a][2],[3]; 4052.2[a][2],-[3]) 7.2.3. Initiating or adjusting the drug regimen of a patient; (BPC 4052.1[a][4], BF 4052.2[a][4]) 7.2.4. Performing moderate or waived laboratory tests. Prior to performing any of these functions, the pharmacist must have either (1) successfully completed clinical residency training, or (2) demonstrated clinical experience in direct paties care delivery as specified in BPC section 4052.2[d]. (BPC 4052.4) 7.2.5. A pharmacist may perform any aspect of any FDA-approved or authorized test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness, condition or disease being tested as applicable. (BPC 4052.4) 7.3. The pharmacist who is authorized to issue an order to initiate or adjust a controlli substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histo of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist or their delegate the CURES information for an individual under the pharmacist or their delegate list for each high-risk patient upon admission of the high-risk patients if the hospital himore than 100 beds, the accurate medication profile is acqu		protocols which have been developed by health professionals including physicians, pharmacists, and registered nurses, with the concurrence of the facility administrator:		
biologicals by injection; (BPC 4052.1[a][2],[3]; 4052.2[a][2],-[3]) 7.2.3. Initiating or adjusting the drug regimen of a patient; (BPC 4052.1[a][4], BF 4052.2[a][4]) 7.2.4. Performing moderate or waived laboratory tests. Prior to performing any of these functions, the pharmacist must have either (1) successfully completed clinical residency training, or (2) demonstrated clinical experience in direct paties care delivery as specified in BPC section 4052.2[d]. (BPC 4052.4) 7.2.5. A pharmacist may perform any aspect of any FDA-approved or authorized test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness, condition or disease being tested as applicable. (BPC 4052.4) 7.3. The pharmacist who is authorized to issue an order to initiate or adjust a controlle substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histo of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist's care. (HSC 11165.1) 7.5. All pharmacists have joined the board's email notification list. (BPC 4013) 7.6 The hospital pharmacist (or pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile c list for each high-risk patient upon admission of the high-risk patients if the hospital humore t				
these functions, the pharmacist must have either (1) successfully completed clinical residency training, or (2) demonstrated clinical experience in direct paties care delivery as specified in BPC section 4052.2[d]. (BPC 4052.4) 7.2.5. A pharmacist may perform any aspect of any FDA-approved or authorized test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness, condition or disease being tested as applicable. (BPC 4052.4) 7.3. The pharmacist who is authorized to issue an order to initiate or adjust a controlli substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histor of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist or their delegate the CURES information for an individual under the pharmacist or their delegate the Curies information for pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile c list for each high-risk patient upon admission of the high-risk patients if the hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may b		=, (-1,-1,,,,,,		
test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness, condition or disease being tested as applicable. (BPC 4052.4) 7.3. The pharmacist who is authorized to issue an order to initiate or adjust a controlle substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histor of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist or their delegate the CURES information for an individual under the pharmacist's care. (HSC 11165.1) 7.5. All pharmacists have joined the board's email notification list. (BPC 4013) 7.6 The hospital pharmacist (or pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile of list for each high-risk patient upon admission of the high-risk patients if the hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.		clinical residency training, or (2) demonstrated clinical experience in direct patient		
substance therapy is personally registered with the federal Drug Enforcement Administration. (BPC 4052[b]) 7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance histor of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist's care. (HSC 11165.1) 7.5. All pharmacists have joined the board's email notification list. (BPC 4013) 7.6 The hospital pharmacist (or pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile of list for each high-risk patient upon admission of the high-risk patients if the hospital hamore than 100 beds, the accurate medication profile is acquired during hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.		test that is classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (42 USC Sec 263a) and the pharmacist completes the testing in a pharmacy laboratory that is licensed in California as a laboratory pursuant to BPC section 1265 unless otherwise authorized in law. The pharmacist has completed necessary training as specified in the pharmacy's policies and procedure maintained in subsection be of BPC section 4119.10 and that allows the pharmacist to demonstrate sufficient knowledge of the illness,		
obtain approval to access information online regarding the controlled substance histo of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist's care. (HSC 11165.1) 7.5. All pharmacists have joined the board's email notification list. (BPC 4013) 7.6 The hospital pharmacist (or pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile of list for each high-risk patient upon admission of the high-risk patients if the hospital hamore than 100 beds, the accurate medication profile is acquired during hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.				
 7.6 The hospital pharmacist (or pharmacy technician or an intern pharmacist if both requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile of list for each high-risk patient upon admission of the high-risk patients if the hospital more than 100 beds, the accurate medication profile is acquired during hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority. 		7.4. All pharmacists have submitted an application to the Department of Justice to obtain approval to access information online regarding the controlled substance history of a patient. Upon approval, the DOJ shall release to the pharmacist or their delegate the CURES information for an individual under the pharmacist's care. (HSC 11165.1)		
requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile of list for each high-risk patient upon admission of the high-risk patients if the hospital more than 100 beds, the accurate medication profile is acquired during hospital pharmacy's hours of operation. (BPC 4118.5) 7.7. The pharmacist may initiate, adjust or discontinue drug therapy for a patient under a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.		7.5. All pharmacists have joined the board's email notification list. (BPC 4013)		
a collaborative practice agreement with any health care provider with prescriptive authority. The collaborative practice agreement may be between a single or multiple pharmacists and a single or multiple health care providers with prescriptive authority.		requirements of BPC 4118.5(b) are met) shall obtain an accurate medication profile or list for each high-risk patient upon admission of the high-risk patients if the hospital has more than 100 beds, the accurate medication profile is acquired during hospital		
(BPC 4052[a][13], [14])				

Yes No N/A	elec phai	Only a prescriber, a prescriber's authorized agent, or a pharmacist may tronically enter a prescription or an order, as defined in BPC 4019, into a macy's or hospital's computer from any location outside of the pharmacy or hospital the permission of the pharmacy or hospital. (BPC 4071.1)
	facil the l orde as e facil orde	A pharmacist located and licensed in the state may, on behalf of a health care ity licensed pursuant to Chapter 2 (commencing with Section 1250) of Division 2 of Health and Safety Code, from a location outside the facility, verify medication charters for appropriateness before administration consistent with federal requirements, stablished in the health care facility's policies and procedures. The health care ity shall maintain a record of the pharmacist's verification of the medication charter that meets the same requirements as those described in Sections 4081 and 4105. C 4071.1[d][1], 4071.1[d][2])
CORRECTIV	/E A0	CTION OR ACTION PLAN:
	of an	Advanced Practice Pharmacist
Yes No N/A		The advanced practice pharmacist has received an advanced practice pharmacist use from the board and may do the following: (BPC 4016.5, 4210)
		8.1.1 Perform patient assessments, order and interpret drug therapy-related tests, and refer patients to other health care providers; (BPC 4052.6[a])
		8.1.2 Participate in the evaluation and management of diseases and health conditions in collaboration with other health care providers; (BPC 4052.6[a])
		8.1.3 Initiate, adjust or discontinue drug therapy and shall promptly transmit written notification to, or enter the appropriate information into a patient record system shared with the patient's primary care provider or diagnosing provider; (BPC 4052.6[a][5], [b])
		8.1.4 Adjust or discontinue drug therapy and promptly transmit written notification to the patient's diagnosing prescriber or enters the appropriate information in a patient's record system shared with the prescriber; (BPC 4052.6[b])
		8.1.5 Prior to initiating or adjusting a controlled substance therapy, the advance practice pharmacist is personally registered with the federal Drug Enforcement Administration; (BPC 4052.6[d])
		8.1.6 Ordering of tests is done in coordination with the patient's primary care provider or diagnosing prescriber, including promptly transmitting written notification to the prescriber or entering information in a patient record system shared with the prescriber. (BPC 4052.6[e])
CORRECTIN	/E A0	CTION OR ACTION PLAN:

9. Duties of an Intern Pharmacist Yes No N/A 9.1. Intern pharmacists are performing all the functions of a pharmacist only under the direct supervision of a pharmacist, and the pharmacist is supervising no more than two interns at any one time. (BPC 4023.5, 4030, 4114, 4119.6, 4119.7, CCR 1726) 9.1.1 Stock, replenish and inspect the emergency pharmaceutical supply container and the emergency medical system supplies. (BPC 4119.6) 9.1.2. Inspect the drugs maintained in the health care facility at least once per month. (BPC 4119.7[c]) 9.2. All prescriptions filled or refilled by an intern are initialed or documented by secure computer entry by a pharmacist prior to dispensing. (CCR 1712[a], 1717[b][1]) 9.3. During a temporary absence of a pharmacist for a meal period or duty-free break, an intern pharmacist does not perform any discretionary duties or act as a pharmacist. (CCR 1714.1[d]) 9.4. The intern hours affidavits are signed by the pharmacist under whom the experience was earned or by the pharmacist-in-charge at the pharmacy while the intern pharmacist obtained the experience, when applicable. (BPC 4209[b], [c], [d]; CCR 1726) 9.5. All intern pharmacists have joined the board's email notification list. (BPC 4013) CORRECTIVE ACTION OR ACTION PLAN: 10. Duties of a Pharmacy Technician Yes No N/A 10.1. Registered pharmacy technicians are performing packaging, manipulative, repetitive, or other nondiscretionary tasks related to the furnishing of drugs, while assisting and under the direct supervision and control of a pharmacist. The pharmacist is responsible for the duties performed by the pharmacy technician under the pharmacist's supervision. (BPC 4023.5, 4038, 4115, CCR 1793.2, CCR 1793.7) 10.2. The ratio is not less than one pharmacist on duty for two technicians when filling prescriptions for an inpatient of a licensed health facility. (BPC 4115[g], CCR 1793.7[f]) 10.3. When prescriptions are dispensed to discharge patients with only one pharmacist, there is no more than one technician performing packaging, manipulative, repetitive, or other nondiscretionary tasks. If a pharmacy technician, under the direct supervision and control of the pharmacist, prepares and administers influenza and COVID-19 vaccines via injection or intranasally, prepares and administers epinephrine, performs specimen collection for tests that are classified as waived under CLIA, receives prescription transfers, and accepts clarification on prescriptions, a second pharmacy technician shall

PIC Initials

not exceed 2:1. (BPC 4038, 4115[g][1], CCR 1793.7[f])

be assisting a pharmacist with performing the tasks as defined in BPC 4115(a). The ratio of pharmacy technicians performing those tasks for additional pharmacists does

Yes No N/A	10.4. Any function performed by a technician in connection with the dispensing of a prescription or chart order, including repackaging from bulk and storage of pharmaceuticals is verified and documented in writing by a pharmacist or documented by a pharmacist using secure computer entry. (CCR 1712, 1793.7)		
	10.5. A pharmacy technician or pharmacy technician trainee wears identification, in 18-point type that identifies them as a pharmacy technician or pharmacy technician trainee (BPC 680, BPC 4115.5[e], CCR 1793.7[d])		
	10.6. The pharmacy has a job description for the pharmacy technician and written policies and procedures to ensure compliance with the technician requirements. (CCR 1793.7)		
	10.7. During a temporary absence of a pharmacist for a meal period or duty-free break, a pharmacy technician may, at the discretion of the pharmacist, remain in the pharmacy but may only perform nondiscretionary tasks. Any task performed by the pharmacy technician during the pharmacist's temporary absence is reviewed by the pharmacist. (BPC 4115[h], CCR 1714.1[c])		
	10.8. The general acute-care hospital has an ongoing clinical pharmacy program and allows specially trained pharmacy technicians to check the work of other pharmacy technicians when the following conditions are met: (CCR 1793.8)		
	 10.8.1. Pharmacists are deployed to the inpatient care setting to provide clinical services. 10.8.2. Compounded or repackaged products are previously checked by a pharmacist, then used by the technician to fill unit dose distribution and floor and ward stock. 10.8.3. The overall operations are the responsibility of the pharmacist-in-charge. 10.8.4. The pharmacy technician checking technician program is under the direct supervision of the Pharmacist as specified in the policies and procedures. 10.8.5. There is an ongoing evaluation of the program that uses specialized and advanced trained pharmacy technicians to check the work of other pharmacy technicians. 		
	10.9. Pharmacy technician duties include the following:		
	 10.9.1. Package emergency supplies for use in the health care facility and the hospital's emergency medical system. (BPC 4119, 4115[j]) 		
	□ 10.9.2. Seal emergency containers for use in the health care facility. (BPC 4115[j])		
	10.9.3. Perform monthly checks of the drug supplies stored throughout the health care facility and report any irregularities within 24 hours to the pharmacist-in- charge and to the director or chief executive officer. (BPC 4115[j])		
	10.10. All pharmacy technicians have joined the board's email notification list. (BPC 4013		
	10.11. A person shall not act as a pharmacy technician without first being licensed by the board as a pharmacy technician. A pharmacy technician certification only is not equivalent to being licensed by the Board as a pharmacy technician. (BPC 4115[f])		
	10.12. A pharmacy technician may, under the direct supervision and control of a pharmacist, prepare and administer influenza and COVID-19 vaccines via injection or		

	intranasally, prepare and administer epinephrine, perform specimen collection for tests that are classified as waived under CLIA, receive prescription transfers, and accept clarification on prescriptions under the following conditions: (BPC 4115[b][1])
	 10.12.1. The pharmacy has scheduled another pharmacy technician to assist the pharmacist by performing the tasks as defined in BPC 4115(a), under the direct supervision of the pharmacist; (BPC 4115[b][1][A])
	□ 10.12.2. The pharmacy technician is certified and maintains the certification, by a pharmacy technician certifying organization offering a pharmacy technician certification program accredited by the National Commission for Certifying Agencies that is approved by the board; (BPC 4115[b][1][B], BPC 4202[a][4])
	□ 10.12.3. The pharmacy technician has completed at least six hours of practical training approved by the Accreditation Council for Pharmacy Education and includes hands-on injection technique, the recognition and treatment of emergency reactions to vaccines, and an assessment of the pharmacy technician's injection technique; (BPC 4115[b][1][C]; and
	 10.12.4. The pharmacy technician is certified in basic life support. (BPC 4115[b][1][D])
	ies of Non-Licensed Personnel
Yes No N/A	11.1. A non-licensed person (clerk/typist) is permitted to type a prescription label or otherwise enter prescription information into a computer record system, and at the direction of a pharmacist, may request and receive refill authorization. (BPC 4007, CCR 1793.3)
	11.2. The number of non-licensed personnel supervised by each pharmacist does not interfere with the effective performance of the pharmacist's responsibilities under the Pharmacy Law. (CCR 1793.3[b])
CORRE	ECTIVE ACTION OR ACTION PLAN:

PHARMACY PRACTICE

12. Pharmaceutical Service Requirements

	12.1. The pharmacy complies with the requirements of 22 CCR 70263, addressing the following areas in written policies and procedures:
	 □ 12.1.1. Basic information concerning investigational drugs and adverse drug reactions; □ 12.1.2. Repackaging and compounding records; □ 12.1.3. Physician orders; □ 12.1.4. Wards, nursing stations and night stock medications; □ 12.1.5. Drugs brought into the facility by patients for storage or use; □ 12.1.6. Bedside medications; □ 12.1.7. Emergency drug supply; □ 12.1.8. Pass medications; □ 12.1.9. Inspection of ward stock, nursing stations and night lockers no less frequently than every 30-days\\Outdated drugs; □ 12.1.10. Routine distribution of inpatient medications; □ 12.1.11. Preparation, labeling and distribution of IV admixtures and cytotoxic agents; □ 12.1.12. Handling of medication when pharmacist not on duty; and
	☐ 12.1.13. Use of electronic image and data order transmissions.
	12.2. The pharmacy complies with the requirements of 22 CCR 70263, addressing the following areas:
	☐ 12.2.1. Destruction of controlled substances; and
	$\hfill\Box$ 12.2.2. Development and maintenance of the hospital's formulary. (22 CCR 70263)
CORREC	CTIVE ACTION OR ACTION PLAN:
13 Madi	cation/Chart Order
Yes No N/A	
	13.1. The pharmacy receives the original, the electronic transmission, or a copy of the medication order. Faxed copies, tele-autograph copies, or transmissions between computers are permissible. (BPC 688, 4019, 4040, CCR 1717.4)
	computers are permissible. (Dr 0 000, 4010, 4040, OOK 1717.4)
	13.2. The chart or medical record of the patient contains all of the information required by BPC 4040 and the chart order is signed by the practitioner authorized by law to prescribe drugs if present or, if not present, within a specified time frame not exceeding 48 hours. (BPC 688, 4019, 4040, 22 CCR 70263[g])

Yes_No N/A	13.4. The pharmacy furnishes dangerous drugs or dangerous devices pursuant to preprinted or electronic standing orders, order sets and protocols established under policies and procedures. (BPC 4119.7)
CORRE	CTIVE ACTION OR ACTION PLAN:
14. Labe	eling and Distribution
	14.1. Unit dose medication are properly labeled and include the information as required by BPC 4076, or the information is otherwise readily available at the time of drug administration. (BPC 4076[b])
	14.2. The pharmacist is responsible for the proper labeling, storage and distribution of investigational drugs pursuant to the written order of the investigator. (22 Cal. Code of Regs 70263[o]).
	14.3. This pharmacy furnishes dangerous drugs in compliance with BPC 4126.5 only to a patient pursuant to a prescription, a wholesaler from whom the dangerous drugs were purchased, a manufacturer from whom the drugs were purchased, a licensed wholesaler acting as a reverse distributor, another pharmacy to alleviate a temporary shortage with a quantity sufficient to alleviate the temporary shortage, a health care provider authorized to receive drugs, to another pharmacy of common ownership, or to a patient or to another pharmacy pursuant to a prescription. (BPC 4126.5[a])
CORRE	CTIVE ACTION OR ACTION PLAN:
	ation of Drug Therapy
Yes No N/A	15.1. The hospital has policies limiting the duration of drug therapy in the absence of the prescriber's specific indication of duration of drug therapy or under other circumstances recommended by the pharmacy and therapeutics committee or its equivalent and approved by the executive committee of the medical staff. Limitations are established for classes of drugs and/or individual drug entities. (22 CCR 70263[j])
CORRE	CTIVE ACTION OR ACTION PLAN:
	fidentiality of Chart Orders, Prescriptions and Patient Medical Information
Yes No N/A	16.1. Patient information is maintained to safeguard confidentiality. (Civil Code 56 et seq.)

Yes No N/A	16.2. Patient medical information, all prescriptions (chart orders, patient discharge and employee prescriptions) are confidential and are not disclosed unless authorized by law. (BPC 4040, CCR 1764, Civil Code 56 et seq.)
	16.3. Destruction or disposal of patient records preserves the confidentiality of the information contained therein. (Civil Code 56.101)
	16.4. The pharmacy ensures electronically transmitted prescriptions (chart orders, discharge patient or employee prescriptions) are received, maintained and transmitted in a secure and confidential manner. (BPC 688, CCR 1717.4)
	16.5. Records regarding dangerous drugs and dangerous devices stored off-site (only for pharmacies who have obtained a waiver from the Board of Pharmacy to store records off-site) are secure and retrievable within two business days. (BPC 4105, CCR 1707)
	Date Waiver Approved Waiver Number
	Address of offsite storage location:
	16.6. Records for non-controlled substances are maintained on the licensed premises for at least one year from the date of dispensing. Records for controlled substances are maintained on the licensed premises for at least two years from the date of dispensing. (BPC 4105, CCR 1707)
	ity Assurance and Medication Errors
Yes No N/A	17.1. Pharmacy has established quality assurance program that documents medication errors attributable, in whole or in part, to the pharmacy or its personnel. (BPC 4125, CCR 1711)
	17.2. Pharmacy quality assurance policies and procedures are maintained in the pharmacy and are immediately retrievable. (CCR 1711[c])
	17.3. When a medication error has occurred (drug was administered to or by the patient, or resulted in a clinically significant delay in therapy) the pharmacist communicates with the patient or patient's agent that a medication error has occurred and the steps required to avoid injury or mitigate the error. (CCR 1711[c][2][A], 1711 [c][3])
	17.4. When a medication error has occurred (drug was administered to or by the patient, or resulted in a clinically significant delay in therapy) the pharmacist communicates to the prescriber that a medication error has occurred. (CCR 1711[c][2][B], 1711 [c][3])
	47.5 Investigation of all amounts and disasting amount is initiated within two business days from
	17.5. Investigation of pharmacy medication errors is initiated within two business days from the date the medication error is discovered. (CCR 1711[d])

		17.6.1. Date, location, and participants in the quality assurance review;
		17.6.2. Pertinent data and other information related to the medication error(s) reviewed;
		17.6.3. Findings and determinations;
		17.6.4. Recommended changes to pharmacy policy, procedure, systems or processes, if any.
Yes No N/A	and	ne record of the quality assurance review is immediately retrievable in the pharmacy is maintained in the pharmacy for at least one year from the date it was created. R 1711[f])
	the	harmacists are not deviating from the requirements of a prescription except upon prior consent of the prescriber, and selection of the drug product is in accordance BPC 4073 (generic substitution). (CCR 1716)
	unli	ne PIC is reporting the quality assurance review reports for medication errors for all censed ADDS to the Board at the time of annual renewal of the hospital pharmacy nse. (CCR 1711[f])
CORREC	CTIVE A	CTION OR ACTION PLAN:
18. Reco	ord Keep	ing Requirements
18. Reco Yes No N/A □□□□	18.1. A	ing Requirements Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715)
Yes No N/A	18.1. A mail 18.2. A for a or p of a	ll completed pharmacy self-assessments are on file in the pharmacy and are
Yes No N/A	18.1. A mail 18.2. A for a or p of a	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records cquisition and disposition or other drug or dispensing-related records maintained
Yes No N/A	18.1. A mail 18.2. A for a or p of a	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include:
Yes No N/A	18.1. A main 18.2. A for a or p of a elect	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include: 18.2.1. Prescription records (BPC 4081[a])
Yes No N/A	18.1. A main 18.2. A for a or p of a elect	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include: 18.2.1. Prescription records (BPC 4081[a]) 18.2.2. Purchase Invoices and sales records for all prescription drugs (BPC 4081)
Yes No N/A	18.1. A main 18.2. A for a or p of a elect	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include: 18.2.1. Prescription records (BPC 4081[a]) 18.2.2. Purchase Invoices and sales records for all prescription drugs (BPC 4081) 18.2.3. Biennial controlled substances inventory (21 CFR 1304.11) 18.2.4. U.S. Official Order Forms (DEA Form-222) (21 CFR 1305.13, 21 CFR
Yes No N/A	18.1. A main 18.2. A for a or p of a elect	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include: 18.2.1. Prescription records (BPC 4081[a]) 18.2.2. Purchase Invoices and sales records for all prescription drugs (BPC 4081) 18.2.3. Biennial controlled substances inventory (21 CFR 1304.11) 18.2.4. U.S. Official Order Forms (DEA Form-222) (21 CFR 1305.13, 21 CFR 1305.22)
Yes No N/A	18.1. A main 18.2. A for a or p of a elect	Il completed pharmacy self-assessments are on file in the pharmacy and are ntained for three years. (CCR 1715) Il drug acquisition and disposition records (complete accountability) are maintained at least three years. Any record maintained electronically, the pharmacist-in-charge harmacist on duty is able to produce a hardcopy and electronic copy of all records equisition and disposition or other drug or dispensing-related records maintained tronically. These records include: 18.2.1. Prescription records (BPC 4081[a]) 18.2.2. Purchase Invoices and sales records for all prescription drugs (BPC 4081) 18.2.3. Biennial controlled substances inventory (21 CFR 1304.11) 18.2.4. U.S. Official Order Forms (DEA Form-222) (21 CFR 1305.13, 21 CFR 1305.22) 18.2.5. Power of Attorney for completion of DEA 222 forms (21 CFR 1305.05)

		18.2.9. Centrally stored unused medications donated to a drug repository and distribution program. (HSC 150200, 150202[a][1], 150204[k], BPC 4105[c]).
		18.2.10. Records documenting, to the extent possible, the kind and amounts of COVID-19 oral therapeutics furnished following a positive test for SARS-CoV-2, as well as information regarding any testing services provided, in the patient's record in the record system maintained by the pharmacy. (BPC 4052.04[d])
Yes No N/A	the perc	ransfers or sales to other pharmacies and prescribers do not exceed five percent of pharmacy's total annual purchases of dangerous drugs or devices. If more than five cent, registration with the board as a wholesaler has been obtained. (21 CFR 7.11, Drug Supply Chain Security Act (DSCSA), BPC 4160)
	pres units patie DEA	sales or distributions of controlled substances to other hospitals, pharmacies, or scribers exceed five percent of the total number of controlled substances dosage is (that are furnished to the inpatients or dispensed on prescriptions to discharge ents or employees) per calendar year, the following have been obtained: a separate A distributor registration and a wholesaler's permit from the board. (21 CFR 1307.11, CSA, BPC 4160)
	18.5. A	controlled substances inventory is completed biennially (every two years).
	Date	e completed: (21 CFR 1304.11)
		Il completed controlled substances inventories are available for inspection for three s. (CCR 1718)
		eparate Schedule II records are maintained. This includes triplicate prescriptions, ices, US official order forms and inventory records. (21 CFR 1304.04)
	or m	ventories and records for Schedule III-V controlled substances are filed separately naintained in a readily retrievable manner that distinguishes them from other nary business records. (21 CFR 1304.04)
	18.9. D	EA Forms 222 are properly executed. (21 CFR 1305.12)
	regis	When the pharmacy distributes Schedule II controlled substances to other DEA strants, Copy 2 of the DEA Form 222, properly completed, are submitted at the end ach month to the DEA Regional Office. (21 CFR 1305.13)
	disc Pha caus	Any controlled substances drug loss is reported within one business day of overy to the DEA and within 30 days after the date of discovery to the Board of rmacy of any loss of controlled substances in one of the following categories that sees the aggregate amount of unreported losses discovered in that category, on or the same day of the previous year, to equal or exceed: (21 CFR 1301.74[c], CCR 5.6)
		18.11.1. Tablets, capsules, or other oral medication, 99 dosage units
		18.11.2. Single-dose injectable medications, lozenges, film, such as oral, buccal and sublingual, suppositories, or patches, 10 dosages units.
		18.11.3. Injectable multi-dose medications, medications administered by continuous infusion, or any other multi-dose unit not described in 18.11.1, two or more multi-dose vials, infusion bags or other containers.

Yes No N/A	E k F r	2. Records stored off-site (only for pharmacies who have obtained a waiver from the Board of Pharmacy to store records off-site) are secure and retrievable within two business days. Records for non-controlled substances are maintained on the licensed premises for at least one year from the date of dispensing. Controlled substances are maintained on the licensed premises for at least two years from the date of dispensing. CCR 1707)
	t F F t	3. Do pharmacy staff hand initial prescription records and prescription labels, OR does he pharmacy comply with the requirement for a pharmacist to initial or sign a prescription record or prescription label by recording the identity of the reviewing pharmacist in a computer system by a secure means. This computer does not permit the record to be altered after made and the record of the pharmacist's identity made in the computer system is immediately retrievable in the pharmacy. (CCR 1712, 1717)
CORRE	CTIVE	E ACTION OR ACTION PLAN:
19. Inve	entory	Reconciliation Report of Controlled Substances
		. The pharmacy performs periodic inventory and inventory reconciliation functions to ect and prevent the loss of controlled substances. (CCR 1715.65[a])
	reco loss	2. The pharmacist-in-charge of the pharmacy reviews all inventory and inventory onciliation reports taken, and establishes and maintains secure methods to prevent es of controlled drugs. Written policies and procedures are developed for performing inventory reconciliation reports required by pharmacy law. (CCR 1715.65[b])
	cont	B. A pharmacy compiles an inventory reconciliation report of all federal Schedule II trolled substances at least every three months. This compilation shall require: (CCR 5.65[c])
		19.3.1. A physical count, not an estimate, of all quantities of federal Schedule II controlled substances. The biennial inventory of controlled substances required by federal law may serve as one of the mandated inventories under this section in the year where the federal biennial inventory is performed, provided the biennial inventory was taken no more than three months from the last inventory required by this section; (CCR 1715.65[c][1])
		19.3.2. A review of all acquisitions and dispositions of federal Schedule II controlled substances since the last inventory reconciliation report; (CCR 1715.65[c][2])
		19.3.3. A comparison of the two above-mentioned items to determine if there are any variances; (CCR 1715.65[c][3])
		19.3.4. All records used to compile each inventory reconciliation report shall be maintained in the pharmacy or clinic for at least three years in a readily retrievable form; and (CCR 1715.65[c][4])

		19.3.5. Possible causes of overages shall be identified in writing and incorporated into the inventory reconciliation report. (CCR 1715.65[c][5])
		19.3.6. In addition to Schedule II controlled substance, the pharmacy is performing an inventory reconciliation of alprazolam 1mg/unit, alprazolam 2mg/unit, tramadol 50mg/unit, and promethazine with codeine 6.25mg promethazine/10mg codeine per 5ml of product at least every 12 months. (CCR 1715.65[a][2])
		19.3.7. An inventory reconciliation report must be prepared for any identified controlled substances lost no later than three months after discovery of the reportable loss. (CCR 1715.65)
		19.3.8. Inventory activities for all other controlled substances must be performed at least once every two years from the performance of the last inventory activities. (CCR 1715.65[a][3][B])
		19.3.9. The inventory reconciliation report may use a digital or electronic signature or biometric identifier in lieu of a physical signature if, in addition, the individual physically signs a printed statement confirming the accuracy of the inventory or report. The signature shall be dated, and the signed and dated statement shall be retained on file. (CCR 1715.65[e][1])
		19.3.10. Inpatient hospital pharmacy, the inventory reconciliation for all federal Schedule II-controlled substances, and alprazolam 1mg/unit, alprazolam 2mg/unit, tramadol 50mg/unit, and promethazine with codeine (6.25mg promethazine/10mg codeine/5ml) must be performed on a quarterly basis. The report or reports shall include controlled substances stored within the pharmacy, within each pharmacy satellite location, and within each drug storage area in the hospital under the pharmacy's control. (CCR 1715.65[g])
Yes No N/A	with which to ich action	The pharmacy reports in writing identified losses and known causes to the board in 30 days of discovery unless the cause of the loss is theft, diversion, or self-use in the case the report shall be made within 14 days of discovery. If the pharmacy is unable lentify the cause of the loss, further investigation is undertaken to identify the cause and one necessary to prevent additional losses of controlled substances. (BPC 4104, CCR 5.65[d], CCR 1715.6)
	repo Whe	A new pharmacist-in-charge of the pharmacy completes an inventory reconciliation ort as identified in CCR 1715.65 (c) within 30 days of becoming pharmacist-in-charge. En possible, the outgoing pharmacist-in-charge also completes an inventory onciliation report as required in CCR 1715.65 (c). (CCR 1715.65 [f])
	acco	. If the inpatient hospital pharmacy uses an ADDS, inventory in the ADDS may be bunted for under CCR section 1715.65(c)(1) using means other than a physical count. R 1715.65[h])
CORREC	CTIVE	E ACTION OR ACTION PLAN:

20. After-	-Hours Supply of Medication
Yes No N/A	20.1 The pharmacy has a system assuring the prescribed medications are available in the hospital 24 hours a day. (22 CCR 70263[e])
	20.2. The pharmacy maintains a record of the drugs taken from the after-hours supply of medications and the pharmacist is notified of such use. The record includes the name and strength of the drug, the amount taken, the date and time, the name of the patient to whom the drug was administered and the signature of the registered nurse. (22 CCR 70263[n])
CORREC	CTIVE ACTION OR ACTION PLAN:
	Supplies for Use in Medical Emergencies
Yes No N/A	21.1. A supply of drugs for use in medical emergencies only is immediately available at each nursing unit or service area as required. (22 CCR 70263[f])
	21.2. Written policies and procedures have been developed that establish the contents of the supply, procedures for use, restocking and sealing of the emergency drug supply. (22 CCR 70263[f][1], BPC 4115, 4119.6))
	21.3. The emergency drug supply is stored in a clearly marked portable container which is sealed by the pharmacist in such a manner that a seal must be broken to gain access to the drugs. The contents of the container are listed on the outside cover and include the earliest expiration date of any drugs within. (22 CCR 70263[f][2])
	21.4. The pharmacist is responsible for inspection of the drug supply at periodic intervals (no less frequently than every 30 days) specified in the writ-ten policies. Records of the inspection are kept for at least three years. The inspection can be done by a pharmacy technician or pharmacy intern as defined in the pharmacy's written inspection policies and procedures. (22 CCR 70263[f][3], BPC 4115[j][3], 4119.7[c])
CORREC	CTIVE ACTION OR ACTION PLAN:
22. Sche	dule II-V Controlled Substances Floor Stock Distribution Records 22.1. Records for the distribution of Schedule II-V controlled substances floor stock are
	open to inspection by authorized officers of the law and are preserved for at least three years from the date of making. (BPC 4081)
CORREC	CTIVE ACTION OR ACTION PLAN:

	rgency i	Room Dispensing
Yes No N/A		prescriber may dispense a dangerous drug, including a controlled substance, to an ergency room patient if all of the following apply: (BPC 4068[a])
		23.1.1. The hospital pharmacy is closed and there is no pharmacist available in the hospital;
		23.1.2. The dangerous drug is acquired by the hospital pharmacy;
		23.1.3. The dispensing information is recorded and provided to the pharmacy when the pharmacy reopens;
		23.1.4. The hospital pharmacy retains the dispensing information and, if the drug is a schedule II, III, IV or IV controlled substance, transmits the dispensing data to the Department of Justice within one working day from the date the controlled substance is released to the patient. (HSC 11165[d])
		23.1.5. The prescriber determines that it is in the best interest of the patient that a particular drug regimen be immediately commenced or continued, and the prescriber reasonably believes that a pharmacy located outside the hospital is not available and accessible at the time of dispensing to the patient; and
		23.1.6. The quantity of drugs dispensed to any patient pursuant to this section are limited to that amount necessary to maintain uninterrupted therapy during the period when pharmacy services outside the hospital are not readily available or accessible, but shall not exceed a 72-hour supply;
		23.17. If an ADDS is located in the emergency room and is used for dispensing to patients upon discharge, the ADDS is licensed with the Board. (BPC 4427.2[i]).
	acc san	he prescription label contains all the required information and is formatted in ordance with CCR 1707.5 including Patient Centered Labels in at least 12-point s serif typeface for the four required items in the required order. (BPC 4076, CCR 7.5)
		he prescriber shall be responsible for any error or omission related to the drugs pensed. (BPC 4068[b])
	23.4. The brand name or generic name and manufacturer of the prescription drug is accurately identified on the label and prescription record. (BPC 4076, CCR 1717)	
	23.5. Controlled substances are dispensed in prescription containers bearing a federal warning label prohibiting transfer of the drugs. (21 CFR 290.5)	
	23.6. Prescriptions are dispensed in new, senior-adult ease-of-opening tested, and child-resistant containers or in a noncomplying package, only pursuant to the prescription or when requested by the purchaser. (15 USC 1473[b], 16 CFR 1700.15, CCR 1717)	
	23.7. Patient package inserts are dispensed with all estrogen medications (21 CFR 310.515)	
		he pharmacy provides patients with required Black Box Warning Information. R 201.57[c])
	23.9. N	ledication guides are provided on required medications. (21 CFR Part 208)

	23.10. Whenever an opioid prescription drug is dispensed to a patient for outpatient use, the pharmacy prominently displays on the label or container or by a flag or other notification to the container, a notice that states, "Caution: Opioid. Risk of overdose and addiction." (BPC 4076.7).
	23.11. A pharmacist may dispense a drug prescribed pursuant to HSC Section 120582 and label the drug without the name of an individual for whom the drug is intended if the prescription includes the words "expedited partner therapy" or the letters "EPT" and shall provide written notification that describes the right of an individual who received EPT to consult with a pharmacist about the medication dispensed and possible drug interactions. (BPC 4076[f], [h])
	23.12. If emergency department patient dispensing is done via AUDS, the AUDS is licensed by the Board. (BPC 4427.2[i])
	23.13. A practitioner specified in Section 11150 may dispense a controlled substance classified in Schedule II, which may be from a hospital pharmacy inventory, directly to an ultimate user in compliance with BPC 4068(a)(4) & (a)(7): (HSC 11158 & BPC 4068)
CORREC	CTIVE ACTION OR ACTION PLAN:
	narge Medication/Consultation Services
Yes No N/A	24.1. Patients receive information regarding each medication given at the time of discharge. The information includes the use and storage of each medication, the precautions and relevant warnings and the importance of compliance with directions. A written policy has been developed in collaboration with a physician and surgeon, a pharmacist, and a registered nurse and approved by the medical staff that ensures that each patient receives the medication consultation. (BPC 4074, CCR 1707.2)
	24.2. Prescriptions are transmitted to another pharmacy as required by law. (BPC 4072, CCR 1717[c], [f], 1717.4)
	24.3. The prescription label contains all the required information and is formatted in accordance with CCR 1707.5 including Patient Centered Labels in at least 12-point sans serif typeface for the four required items in the required order. (BPC 4076, CCR 1707.5)
	24.4. The pharmacist includes a written label on the drug container indicating that the drug may impair a person's ability to operate a vehicle or vessel. The label may be printed on an auxiliary label affixed to the prescription container. (BPC 4074[a], [b], CCR 1744[a][1]-[7])
	24.5 The pharmacist includes a written label on the drug container to alert the patient about

	printed on an auxiliary label affixed to the prescription container (ΒΡC 4074[a], CCR 1744[b][1]-[6]).
Yes No N/A	24.6. The trade name or generic name and manufacturer of the prescription drug is accurately identified in the prescription record. (CCR 1717)
	24.7. Generic substitution for discharge medications is communicated to the patient, and the name of the dispensed drug product is indicated on the prescription label. (BPC 4073)
	24.8. If the prescription is filled by a pharmacy technician, the pharmacist's initials are on the prescription label to document the pharmacist's verification of the product or can be satisfied by recording the identity of the reviewing pharmacist in a computer system by a secure means and is immediately retrievable in the pharmacy. (CCR 1712, 1793.7)
	24.9. Controlled substances are dispensed in prescription containers bearing a federal warning label prohibiting transfer of the drugs. (21 CFR 290.5)
	24.10. Prescriptions are dispensed in a new and child-resistant container, or senior-adult ease-of-opening tested container, or in a non-complying package only pursuant to the prescriber or when requested by the purchaser. (15 USC 1473, 16 CFR 1700.15, CCR 1717)
	24.11. Patient package inserts are dispensed with all estrogen medications. (21 CFR 310.515)
	24.12. The pharmacy provides patients with required Black Box Warning. (21 CFR 201.57[c])
	24.13. Medication guides are provided on required medications. (21 CFR Part 208)
	24.14. Whenever an opioid prescription drug is dispensed to patient for outpatient use, the pharmacy prominently displays on the label or container or by a flag or other notification to the container, a notice that states, "Caution: Opioid. Risk of overdose and addiction." (BPC 4076.7).
	24.15. The pharmacy has the capability to receive electronic data transmission prescriptions on behalf of patients. (BPC 688)
	24.16. The hospital pharmacy retains the dispensing information and, if the drug is a schedule II, III, IV or V controlled substance, transmits the dispensing data to the Department of Justice within one working day after the date the controlled substance is released to the patient or patient's representative. (HSC 11165[d])
CORREC	CTIVE ACTION OR ACTION PLAN:

25. Cent	ral Filling of Patient Cassettes For Other Hospital Pharmacies		
Yes No N/A	25.1. Pharmacy processes orders for the filling of patient cassettes for another hospital or Pharmacy within this state receives filled medication orders or patient cassettes from another hospital. (CCR 1710[b])		
	If the answer is "yes," name of hospital:		
	25.2. Pharmacy receives filled medication containers or cassettes from another pharmacy. (CCR 1710[b])		
	If the answer is "yes," name of supplying pharmacy:		
	If the answer to this and the previous question is "no" or "not applicable" go to Section 26.		
	25.3. Prescription information is electronically transferred between the two pharmacies. (CCR 1710[b][6])		
	25.4. Pharmacy has a contract with the ordering hospital pharmacy or has the same owner (CCR 1710[b][1])		
	25.5. Filled cassettes are delivered directly to the ordering hospital pharmacy. (CCR 1710[b][2])		
	25.6. Each cassette or container meets the requirements of Business and Professions Code section 4076. (BPC 4076[b], [c], [d], CCR 1710[b][3])		
	25.7. Complete and accurate records are maintained of each cassette fill transaction, including the name of the pharmacist checking the cassettes at each pharmacy. (CCR 1710[b][5])		
26. Cent	ralized Hospital Packaging Pharmacy		
Yes No N/A	26.1 Prior to engaging in centralized hospital packaging, the pharmacy in addition to the hospital pharmacy license, has obtained a Centralized Hospital Packaging specialty license from the Board (BPC 4128.2a)		
Lie	cense Number:		
	26.2. The pharmacy prepares medications, by performing the following specialized functions, for administration only to inpatients within its own general acute care hospital and one or more general acute care hospitals under common ownership and located within a 75-mile radius: (BPC 4128)		
	Hospitals to which central packaged unit dose medications are provided:		
	□ 26.2.1 Distance (miles):		
	□ 26.2.2 Distance (miles):		
	□ 26.2.3 Distance (miles):		
	□ 26.2.4 Distance (miles):		

PIC Initials

	26.2.5. Prepares unit dose packages for single administration to inpatients from bulk containers, if each unit dose package is barcoded pursuant to BPC 4128.4.		
	☐ 26.2.6. Prepares sterile compounded unit dose drugs for administration to inpatients if each compounded unit dose drug is barcoded pursuant to BPC 4128.4.		
	26.2.7. Prepares compounded unit dose drugs for administration to inpatients, if each unit dose package is barcoded pursuant to BPC 4128.4.		
Yes No N/A	26.3. The pharmacy prepares and stores limited quantities of unit dose drugs in advance a patient-specific prescription in amounts necessary to ensure continuity of care. (BF 4128.3)		
	26.4. Any unit dose medications produced by a centralized hospital packaging pharmacy are barcoded to be machine readable at the inpatient's bedside using barcode medication administrative software. (BPC 4128.4)		
	26.4.1. The barcode medication administration software permits health care practitioners to ensure that before a medication is administered to an inpatient, it is the right medication, for the right inpatient, in the right dose, and via the right route of administration. (BPC 4128[a])		
	26.4.2. The software verifies that the medication satisfies the above criteria by reading the barcode on the medication and comparing the information retrieved to the electronic medical record of the inpatient. [BPC 4128(b)]		
	26.5. Any label for each unit dose medication produced by a centralized hospital packaging pharmacy displays a human-readable label that contains the following: (BPC 4128.5[a])		
	 □ 26.5.1. The date the medication was prepared. □ 26.5.2. The beyond-use date □ 26.5.3. The established name of the drug. □ 26.5.4. The quantity of each active ingredient. □ 26.5.5. The lot number or control number assigned by the centralized hospital packaging pharmacy. 		
000	 26.5.6. Special storage or handling requirements. 26.5.7. The name of the centralized hospital packaging pharmacy. 26.6. The pharmacist is able to retrieve all of the following information using the lot number or control number: (BPC 4128.5[b]) 		
	 □ 26.6.1. The components used in the drug product. □ 26.6.2. The expiration date of each of the drug's components. □ 26.6.3. The National Drug Code Directory number. 		
	26.7. The centralized hospital packaging pharmacy and the pharmacists working in the pharmacy are responsible for the integrity, potency, quality, and labeled strength of any unit dose drug product prepared by the centralized hospital packaging pharmacy. (BPC 4128.7)		

CORREC	CTIVE A	CTION OR ACTION PLAN:		
_	27. Policies and Procedures			
Yes No N/A	27.1. T	here are written policies and procedures in place for:		
		27.1.1. Oral consultation for discharge medication to an inpatient of a health care facility licensed pursuant to HSC 1250. The assurance that each patient received information regarding each medication given at the time of discharge. (BPC 4074[e], CCR 1707.2[b][2])		
		27.1.2. Action to be taken to protect the public when a licensed individual employed by or with the pharmacy is known to be chemically, mentally, or physically impaired to the extent that it effects their ability to practice the profession or occupation authorized by their license. (BPC 4104[a])		
		27.1.3. Action to be taken to protect the public when a licensed individual employed by or with the pharmacy is known to have engaged in the theft or diversion or self-use of prescription drugs belonging to the pharmacy. (BPC 4104[b])		
		27.1.4. Addressing chemical, mental, or physical impairment, as well as, theft, diversion, or self-use of dangerous drugs, among licensed individual employees by or with the pharmacy. (BPC 4104[b])		
		27.1.5. Reporting to the board within 14 days of the receipt or development of information as specified in BPC 4104[c][1]-[6].		
		27.1.6. Operation of the pharmacy during the temporary absence of the pharmacist for breaks and meal periods including authorized duties of personnel, pharmacist's responsibilities for checking all work performed by ancillary staff, and pharmacist's responsibility for maintaining the security of the pharmacy. (CCR 1714.1[f])		
		27.1.7. Assuring confidentiality of medical information if your pharmacy maintains the required dispensing information for prescriptions, other than controlled substances, in a shared common electronic file. (CCR 1717.1[e])		
		27.1.8. Helping patients with limited or no English proficiency understand the information on the prescription container label in the patient's language, including the selected means to identify the patient's language and providing interpretive services in the patient's language. (CCR 1707.5)		
		27.1.9. Inventory reconciliation reporting requirements. (CCR 1715.65)		
		27.1.10. Pharmacy technician performing monthly checks of the drug supplies stored throughout the health care facility and reporting irregularities within 24 hours to the pharmacist-in-charge and the director or chief executive officer of the health care facility. (BPC 4115[j][3])		

	Ш	pharmacist, may inspect the drugs maintained in the health care facility at least once per month. (BPC 4119.7[c])
		27.1.12. Furnishing dangerous drug or dangerous device pursuant to preprinted or electronic standing orders, order sets, and protocol, if the order is dated, timed, and authenticated in the medical record of the patient to whom the dangerous drug or dangerous device is provided. (BPC 4119.7[a])
		27.1.13. Storing and maintaining drugs in accordance with national standards regarding storage areas, refrigerator or freezer temperature, and otherwise pursuant to the manufacturer's guidelines. (BPC 4119.7[b], 22 CCR 70263 [c][1], [q][6])
		27.1.14. Establishing the supply contents, procedure for use, restocking and sealing of emergency drug supply. (CCR 70263[f][1])
		27.1.15. If applicable, dispensing, storage and records of use if bedside medications are allowed. No controlled substances shall be left at bedside. (22 CCR 70263[/])
		27.1.16. The use of investigational drugs. Basic information concerning the dosage form, route of administration, strength, actions, uses, side effects, adverse effects, interaction and symptoms of toxicity shall be available in the pharmacy and the nursing station. The pharmacist is responsible for the proper labeling, storage and distribution of such drug pursuant to the investigator's written orders. (22 CCR 70263[o]).
		CTION OR ACTION PLAN:
28. Con Yes No N/A	npoundi	ng
	28.1 Prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-charge must complete the "Compounding Self-Assessment" as required by CCR 1735.2. (CCR 1735.2)	
	omated I	Drug Delivery Systems
Yes No N/A □□□□	29.1. The hospital pharmacy operates automated drug delivery systems that are automate unit dose systems (AUDS) for doses administered at the facility and approved services listed on the hospital's license and the ADDS is/are exempt from licensure with the board. The AUDS must comply with all other requirements for an ADDS in Article 25. (BPC 4427.2[i])	
	29.2. The hospital pharmacy operates automated drug delivery systems that are automate patient delivery dispensing systems (APDS) for doses dispensed to patients at the facility and approved services listed on the hospital's license and the ADDS is/are licensed with the board. (BPC 4427.2[a])	

Yes No N/A	29.3. If the pharmacy operates an automated drug delivery system, the pharmacist-in-charge has completed the self-assessment for automated drug delivery systems pursuant to CCR 1715. The pharmacy shall comply with all recording keeping and quality assurance requirements and maintain those records within the licensed pharmacy holding the ADDS license and separate from other pharmacy records. (BPC 4427.7)
CORREC	CTIVE ACTION OR ACTION PLAN:
	cription Drug Take-Back Services
Yes No N/A	30.1. Does the pharmacy participate in a Prescription Drug Take-Back Program and adheres to the federal, state, and local requirements governing the collection and destruction of dangerous drugs? (CCR 1776, 1776.1)
	If yes, check off below the type of prescription drug take-back program the pharmacy offers and complete the sections that apply to the type of program(s):
	 □ Mail back envelopes or package service. (CCR 1776.2) □ Collection receptacles in the pharmacy. (CCR 1776.3) □ Drug take-back services in the Skilled Nursing Facilities. (CCR 1776.4, HSC 1250[c])
	30.2. Only prescription drugs that have been dispensed by any pharmacy or practitioner to a consumer are eligible for collection as part of drug take-back services maintained by the pharmacy. (CCR 1776.1[f])
	30.3. Dangerous drugs that have not been dispensed to consumers for use (such as outdated drug stock, drug samples provided to medical practitioners or medical waste) are not collected as part of the pharmacy's drug take-back service. (CCR 1776.1[f])
	30.4. The pharmacy does not accept or possess prescription drugs from skilled nursing facilities, residential care homes, health care practitioners or any other entity as part of its drug take-back services. (CCR 1776.1[g][2])
	30.5. Quarantined, recalled or outdated prescription drugs from the pharmacy stock are not disposed as part of the pharmacy's drug take-back services. (CCR 1776.1[g][3])
CORREC	CTIVE ACTION OR ACTION PLAN:

Pharmac	ies Offering Mail Back Envelopes or Package Services (CCR 1776.1, 1776.2)		
Yes No N/A	30.6. The pharmacy provides prescription drug take-back preaddressed mailing envelopes or packages to consumers to return prescription drugs to an authorized destruction location. (CCR 1776.2[a])		
	30.7. All drug take-back envelopes and packages made available to the public are preaddressed to a location registered with the DEA as a collector. (CCR 1776.2[b])		
	30.8. The preaddressed envelopes and packages are water and spill proof, tamper evident, tear resistant and sealable. The exterior is nondescript and has no markings indicating the envelope or package contains prescription drugs. Postage is prepaid on each envelope or package. (CCR 1776.2[c])		
	30.9. The preaddressed envelope and package contains a unique identification number for each envelope and package, and the instructions for users indicates the process to mail back the drugs. (CCR 1776.2[d])		
	30.10. The pharmacy does not accept any mail back packages or envelopes containing drugs unless the pharmacy is registered as a collector and has an onsite method of destruction that complies with DEA requirements. The consumer is directed to mail the envelopes or packages. (CCR 1776.2[e])		
	If the answer is no and the pharmacy is registered with DEA as a collector with an onsite method of destruction that complies with DEA requirements, list the following (21 CFR 1317.40):		
	DEA Collector Registration Number:		
	Expiration Date:		
	30.11. Once drugs are deposited into a mail back envelope or package by the consumer, the pharmacy does not remove, count, sort or individually handle any prescription drugs from the consumer. (CCR 1776.1[d], [g])		
CORREC	TIVE ACTION OR ACTION PLAN:		
Pharmac Yes No N/A	ies with Collection Receptacles in the Pharmacy/Hospital (CCR 1776.1, 1776.3)		
	30.12. The pharmacy is registered with DEA as a collector for purposes of maintaining a prescription drug take-back collection receptacle. (21 CFR 1317.30, 1317.40, CCR 1776)		
	30.13. The pharmacy notified the board in writing within 30 days of establishing the collection program. (CCR 1776.1[i])		
	Date the board was notified:		

Yes No N/A	30.14. When the pharmacy renewed its pharmacy license, the pharmacy identified and disclosed to the board all the locations where its collection receptacles are located. (CCR 1776.1[i][2])			
	30.15. The pharmacy is aware, any tampering with a collection receptacle or theft of deposited drugs and any tampering, damage or theft of the removed liner are reported to the board in writing within 14 days. (CCR 1776.1[i][3][4])			
	List the dates the board was notified of any tampering or theft from the collection receptacle and/or tampering, damage or theft of the removed liner:			
	Date reported:			
	30.16. The pharmacy is not on probation with the board. (CCR 1776.1[I])			
	If answered NO, meaning the pharmacy is on probation, the pharmacy cannot maintain a drug take back collection receptacle and must cease and notify the board in writing within 30 days and notify the DEA within 30 days.			
	30.17. Once drugs are deposited into a collection receptacle by the consumer, the pharmacy does not remove, count, sort or individually handle any prescription druftom the consumer. (CCR 1776.1[d], 1776.3[e])			
	30.18. The collection receptacle is substantially constructed with a permanent outer container, removable inner liner, and is locked at all times to prevent access to the ir liner. (CCR 1776.3[a], [d])			
	30.19. The collection receptacle is securely fastened to a permanent structure so it can be removed and is installed in an inside location. (CCR 1776.3[b])			
	30.20. The receptacle is visible to the pharmacy and DEA registrant employees, but no located in or near emergency areas, nor behind the pharmacy's counter or is locate an area that is regularly monitored by pharmacy or DEA registrant employees and registrant of any emergency or urgent care areas. When no pharmacy or DEA registrant employees are present, the collection receptacle is locked so that drugs a not deposited into the collection receptacle. (CCR 1776.3[b], [c])			
	30.21. The receptacle includes a small opening that allows deposit of drugs into the inside of the receptacle directly into the inner liner, but does not allow for an individual to reach into the receptacle's contents. When the pharmacy is closed, the collection receptacle is not accessible to the public for deposit of drugs. The pharmacy locks the deposit opening on the collection receptacle. (CCR 1776.3[d])			
	30.22. The pharmacy directs consumers to directly deposit the drugs into the collection receptacle. (CCR 1776.3[e])			
	30.23. The inner liner used is made of material that is certified by the manufacturer to meet the ASTM D179 standard test for impact resistance of 165 grams (drop dart test) and the ASTM D1922standards for tear resistance of 480 grams in both parallel and perpendicular planes. (CCR1776.3[f])			
	□ 30.23.1 The liner is waterproof, tamper evident, tear resistant, and opaque to prevent viewing or removal of any contents once the liner has been removed from the collection receptacle. (CCR 1776.3[f])			

	□ 30.23.2 The liner is clearly marked to display the maximum contents (for example in gallons). (CCR 1776.3[g])		
	 30.23.3 The liner bears a permanent, unique identification number established by the pharmacy or pre-entered onto the liner by the liner's manufacturer or distributor. (CCR 1776.3[f][2]) 		
	□ 30.23.4 The liner is removable as specified pursuant to CCR 1776.3. (CCR 1776.3[f][2])		
Yes No N/A	30.24. The receptacle allows the public to deposit prescription drugs into the receptacle for containment into the inner liner, without permitting access to or removal of prescription drugs already deposited into the collection receptacle and liner. Once the prescription drugs or any other item is placed in the collection receptacle, the prescription drug or item cannot be removed, counted, sorted, or otherwise individually handled. (CCR 1776.3[d], [e], [g])		
	30.25. If the liner is not already itself rigid or already inside of a rigid container when it is removed from the collection receptacle, the liner is immediately, without interruption, placed in a rigid container for storage, handling and transport. (CCR 1776.3[h])		
	30.26. The liner is removed from a locked collection receptacle only by or under the supervision of two employees of the pharmacy. Upon removal, the liner is immedia without interruption, sealed and the pharmacy employees record, in a log, their participation in the removal of each liner from the collection receptacle. Liners and rigid containers are not opened, x-rayed, analyzed, or penetrated at any time by the pharmacy or pharmacy personnel. (CCR 1776.3[i])		
	30.27. Liners and their rigid containers that are filled and removed from the collection receptacle is stored in a secured, locked location in the pharmacy no longer than 14 days. (CCR 1776.3[j])		
	30.28. The pharmacy maintain records for collected unwanted drugs from consumers for three years, including the records for each liner. (CCR 1776.3[k], 1776.6[a])		
	30.29. The pharmacy seals the inner liners and their contents are shipped to a reversed distributor's registered location by common or contract carrier (such as UPS, FEDEX, USPS) or by a licensed reverse distributor pick up at the licensed pharmacy's premise. (CCR 1776.3[I])		
	30.30. The collection receptacle has a signage that includes: (1) the name and phone number of the responsible pharmacy, (2) medical sharps and needles (e.g. insulin syringes) shall not to be deposited, and (3) consumers may deposit prescription drugs including Schedule II-V controlled substance. (CCR 1776.1[e], 1776.3[m])		
CORRE	CTIVE ACTION OR ACTION PLAN:		

Onsite Pharmacies with Drug Take-Back Services in Skilled Nursing Facilities Yes No N/A 30.31. The pharmacy provides mail back envelopes or packages to skilled nursing facility employees or persons lawfully entitled to dispose of a resident decedent's property of unwanted or unused prescription drugs. (CCR 1776.4[a]) 30.32. If the pharmacy provides mail back envelopes or packages to skilled nursing facilities, the skilled nursing facility employees keeps a record noting the specific quantity of each prescription drug mailed back, the unique identification number of the mail back package and the preaddressed location to which the mail back envelope is sent. (CCR 1776.4[a]) 30.33. If the pharmacy is onsite at a skilled nursing facility, has the pharmacy established a collection receptacle in the skilled nursing facility for the collection and ultimate disposal of unwanted prescription drugs? (CCR 1776.4[b]) If no, answer N/A to the remaining questions in this section. If yes, continue answering the questions in this section. List the location(s) of the collection receptacle: 30.34. The board was notified in writing within 30 days of establishing a collection receptacle. (CCR 1776.4[b][2]) 30.35. Has there been any tampering of the collection receptacle, theft of the deposited drugs and/or tampering, damage or theft of the removed liner? (CCR 1776.4[b][4], [5]) If yes, was the board notified in writing within 14 days of any tampering of the collection receptacles and/or liner? 30.36. When the pharmacy license was renewed, the pharmacy provides the list a current list of collection receptacles. (CCR 1776.4[b][6]) 30.37. The skilled nursing facility places a patient's unneeded prescription drugs into a collection receptacle within three business days after the permanent discontinuance of use of a medication by a prescriber, as a result of the resident's transfer to another facility or as a result of death. Records of such deposit is made in the patient's records, with the name and signature of the employee discarding the drugs. (CCR 1776.4[d]) 30.38. The collection receptacle is located in a secured area regularly monitored by the skilled nursing facility employees, securely fastened to a permanent structure so it cannot be removed, has a small opening that allows deposit of drugs into the inside of the collection receptacle and directly into the inner liner, but does not allow for an individual to reach into the receptacle's contents, securely locked and substantially constructed with a permanent outer container and a removable inner liner. (CCR 1776.4[e][f][g]) 30.39. The liner is certified by the manufacturer to meet the American Society for Testing Materials(ASTM) D1709 standard test for impact resistance of 165 grams (drop dart test) and the ASTM D1922standards for tear resistance of 480 grams in both parallel

	the collection receptacle, marked to display the maximum contents, and bear a permanent, unique identification number. (CCR 1776.4[h])
Yes No N/A	30.40. The receptacle allows the deposit of prescription drugs into the receptacle for containment into the inner liner, without permitting access to or removal of prescription drugs already deposited into the collection receptacle and liner. Once a prescription drug or item is placed in the collection receptacle, the prescription drug or item cannot be removed, sorted, counted, or otherwise individually handled. (CCR 1776.4[g][1])
	30.41. If the liner is not already itself rigid or already inside a rigid container when it is removed from the collection receptacle, the liner is immediately placed in a rigid container for storage, handling and transport. (CCR 1776.4[g][2])
	30.42. The rigid container is either disposable, reusable, or recyclable. The rigid container is leak resistant, has sealable tight fitting covers and kept clean and in good repair. (CCR 1776.4[g][2])
	30.43. The collection receptacle contains signage with (1) the name and phone number of the pharmacy, (2) medical sharps and needles (e.g. insulin syringes) cannot be deposited, and (3) consumers may deposit prescription drugs including Schedule II-V controlled substances. (CCR 1776.4[i])
	30.44. Once deposited, the prescription drugs are not counted, sorted, or otherwise individually handled. (CCR 1776.4[j])
	30.45. The installation, removal, transfer, and storage of inner liners is performed only by (1) one employee of the authorized collector pharmacy and one supervisory level employee of the long term care facility (e.g. charge nurse or supervisor) designated by the authorized collector or (2) by or under the supervision of two employees of the authorized collector pharmacy. (CCR 1776.4[k])
	30.46. Sealed inner liners placed in a container are stored at the skilled nursing facility up to three business days in a securely locked, substantially constructed cabinet or a securely locked room with controlled access until transfer to a reverse distributor for destruction. (CCR 1776.4[I])
	30.47. Liners housed in a rigid container are delivered to a reverse distributor for destruction by a common or contract carrier or by a reverse distributor picked up at the skilled nursing facility. (CCR 1776.4[m])
CORREC	CTIVE ACTION OR ACTION PLAN:

and perpendicular planes, is waterproof, tamper evident, tear resistant, and opaque to prevent viewing and discourage removal of any contents once the liner is removed from

Record k	Keeping	Requirements for Board Licensees Providing Drug Take Back Services		
Yes No N/A	30.48. Records required for drug take back services are maintained for three years. (CCF 1776.6)			
	30.49. The pharmacy makes and keeps the following records for each liner: (CCR 1776.6[a])			
		30.49.1. The date each unused liner is acquired, its unique identification number and size (e.g. 5 gallon, 10 gallon). If the liner does not already contain a unique identification number, the pharmacy assigns the unique identification number. (CCR 1776.6[a][1])		
		30.49.2. The date each liner is installed in a collection receptacle, the address of the location where each liner is installed, the unique identification number and size (e.g., 5 gallon, 10 gallon), the registration number of the collector pharmacy, and the names and signatures of the two employees that witnessed each installation. (CCR 1776.6[a][2])		
		30.49.3. The date each inner liner is removed and sealed, the address of the location from which each inner liner is removed, the unique identification number and size (e.g. 5 gallon, 10 gallon) of each inner liner removed, the registration number of the collector pharmacy, and the names and signatures of the two employees that witnessed the removal and sealing. (CCR 1776.6[a][3])		
		30.49.4. The date each sealed inner liner is transferred to storage, the unique identification number and size (e.g., 5 gallon, 10 gallon) of each inner liner stored, and the names and signatures of the two employees that transferred each sealed inner liner to storage. (CCR 1776.6[a][4])		
		30.49.5. The date each sealed inner liner is transferred for destruction, the address and registration number of the reverse distributor or distributor to whom each sealer inner liner was transferred, the unique identification number and size (e.g., 5 gallon, 10 gallon) of each liner transferred, and the names and signatures of the two employees who transferred each sealed inner liner to the reverse distributor or distributor, or the common carrier who delivered it, the company used, and any related paperwork (invoice, bill of lading). (CCR 1776.6[a][5])		
CORREC	CTIVE AC	CTION OR ACTION PLAN:		

PHARMACIST-IN-CHARGE CERTIFICATION:

I, (please print) that I have completed the self-assessment of this p Any deficiency identified herein will be corrected by responses are subject to verification by the Board of perjury of the laws of the State of California that the assessment form is true and correct.	/ (date) of Pharmacy. I further	. I understand that all state under penalty of
Signature*		Date
(Pharmacist-in-Charge)		
ACKNOWLEDGEMENT BY HOSPITAL ADMINIS	TRATOR:	
I, (please print)	entified in this self-ass above could result in	essment in the timeframe
Signature*		Date
(Hospital Administrator)		
*Consistent with the Board's policy statement, the E	Board will accept digita	al signatures.

The following **Legal References** are used in the self-assessment form. Many of these references can be viewed on the Board of Pharmacy Web site at www.pharmacy.ca.gov (see *Laws and Regulations*), at the California State Law Library, or at other libraries or Internet web sites.

- Business and Professions Code (BPC), Division 2, Chapter 1 General Provisions
- BPC, Division 2, Chapter 9 Pharmacy
- California Code of Regulation (CCR), Title 16, Division 17 California State Board of Pharmacy
- CCR, Title 22, Division 5, Chapter 1 General Acute Care Hospitals
- Civil Code, Division 1, Part 2.6, Chapter 2 Disclosure of Medical Information by Providers
- Code of Federal Regulations (CFR), Title 16, Chapter II, Subchapter E, Part 1700 Poison Prevention Packaging
- CFR, Title 21, Chapter I, Subchapter C, Part 201, Subpart B Labeling Requirements for Prescription Drugs and/or Insulin
- CFR, Title 21, Chapter I, Subchapter C, Part 208 Medication Guides for Prescription Drug Products
- CFR, Title 21, Chapter I, Subchapter C, Part 290 Controlled Drugs
- CFR, Title 21, Chapter I, Subchapter D, Part 310, Subpart E Requirements for Specific New Drugs and Devices
- CFR, Title 21, Chapter II Drug Enforcement Administration, Department of Justice
- Health and Safety Code (HSC), Division 10 Uniform Controlled Substances Act
- HSC, Division 104, Part 5 (Sherman Food, Drug, and Cosmetics Law), Chapter 2 Administration
- HSC, Division 116 Surplus Medication Collection and Distribution
- United States Code (USC), Title 15, Chapter 39A Special Packaging of Household Substances for Protection of Children
- USC, Title 21, Chapter 9, Subchapter V, Part H Pharmaceutical Distribution Supply Chain (Drug Supply Chain Security Act)